New 2021 Forecasts Released

New Data
innovation hub

Mnemosyne Pharmaceuticals is Profiled in this Database

Updated At 30 Apr, 2012

Start Free 7 Day Trial Now
Partial description of this company
First-in-class subunit-selective NMDA receptor modulators to treat neuropsychiatric diseases, specifically schizophrenia and Alzheimer\'s

Start Trial Get Full Profile

There’s no risk. Start your trial today to see profiles of Mnemosyne Pharmaceuticals plus 4810 other startups.

Start Free 7 Day Trial Now

Learn More About Mnemosyne Pharmaceuticals

Technology/product details

Revenue projections

Capital raised to date

Growth strategy

More

Start Free 7 Day Trial Now

Our Clients

1-jnj.png
2-medtronic.png
3-abbott.png
4-baxter.png
7-bostonscientific.png
8-bd.png
9-smithnephew.png
10-stryker.png
33m.png
allergan.jpg
bain.jpg
bbraun.png
beckmancoulter.png
cardinal.png
depuysynthes.png
drager.png
edwardslifesciences.png
ethicon.png
ge.png
gore.png
health-advances.jpg
hospira.png
jlabs.jpg
kimberlyclark.png
merck.jpg
olympus.png
orthofix.png
philips.png
sanofigenzyme.png
teleflex.jpg
terumo.png
zimmerbiomet.png